American Century Companies
NKTR icon

American Century Companies’s Nektar Therapeutics NKTR Stock Holding History

American Century Companies’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,998
Closed -$28.6K – 2822
2023
Q1 		$28.6K Buy
2,998
+542
+22% +$16.4K ﹤0.01% 2653
2022
Q4 		$83.3K Buy
2,456
+1,339
+120% +$64.8K ﹤0.01% 2487
2022
Q3 		$54K Buy
+1,117
New +$66.5K ﹤0.01% 2396
2018
Q2 		– Sell
-5,937
Closed -$9.46M – 1337
2018
Q1 		$9.46M Buy
+5,937
New +$7.65M 0.01% 653
2015
Q4 		– Sell
-35,063
Closed -$5.76M – 1358
2015
Q3 		$5.76M Buy
35,063
+4,450
+15% +$787K 0.01% 789
2015
Q2 		$5.75M Buy
+30,613
New +$5.27M 0.01% 797
2015
Q1 		– Sell
-21,808
Closed -$5.07M – 1412
2014
Q4 		$5.07M Buy
21,808
+556
+3% +$119K 0.01% 848
2014
Q3 		$3.85M Buy
21,252
+695
+3% +$133K ﹤0.01% 942
2014
Q2 		$3.95M Buy
20,557
+13,234
+181% +$2.34M ﹤0.01% 962
2014
Q1 		$1.33M Buy
7,323
+1,674
+30% +$331K ﹤0.01% 1172
2013
Q4 		$962K Buy
5,649
+343
+6% +$55.3K ﹤0.01% 1253
2013
Q3 		$832K Buy
5,306
+337
+7% +$62.3K ﹤0.01% 1269
2013
Q2 		$861K Buy
+4,969
New +$762K ﹤0.01% 1229

Other funds holding NKTR

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

American Century Companies's NKTR Position: Q2 2023 in Review

American Century Companies sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 2,998 shares — an estimated $28.6K sold.

American Century Companies first reported a position in NKTR in Q2 2013 and held it in 13 quarters. The position peaked at $9.46M in Q1 2018. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

  • American Century Companies reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
  • American Century Companies sold 2,998 Nektar Therapeutics shares in Q2 2023, an estimated $28.6K.
  • American Century Companies first reported a position in Nektar Therapeutics in Q2 2013 and held it in 13 quarters.
  • American Century Companies's Nektar Therapeutics position peaked at $9.46M in Q1 2018.
  • 146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on American Century Companies's 13F filing for Q2 2023, filed 14 Aug 2023.